FDA Approves Enzalutamide for Nonmetastatic Prostate Cancer

Share this post

The oral therapy becomes the second androgen receptor-targeting therapy to be approved for use in this earlier disease setting.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply